| Literature DB >> 34287760 |
S Honig1, H Diener2, T Kölbel2, W Reinpold3, A Zapf4, E Bibiza-Freiwald4, E S Debus2.
Abstract
The reported incidence of incisional hernia following repair of abdominal aortic aneurysm (AAA) via midline laparotomy is up to 69%. This prospective, multicenter, double-blind, randomised controlled trial was conducted at eleven hospitals in Germany. Patients aged 18 years or older undergoing elective AAA-repair via midline incision were randomly assigned using a computer-generated randomisation sequence to one of three groups for fascial closure: with long-term absorbable suture (MonoPlus®, group I), long-term absorbable suture and onlay mesh reinforcement (group II) or extra long-term absorbable suture (MonoMax®, group III). The primary endpoint was the incidence of incisional hernia within 24 months of follow-up, analysed by intention to treat. Physicians conducting the postoperative visits and the patients were blinded. Between February 2011 and July 2013, 104 patients (69.8 ± 7.7 years) were randomised, 99 of them received a study intervention. The rate of incisional hernia within 24 months was not significantly reduced with onlay mesh augmentation compared to primary suture (p = 0.290). Furthermore, the rate of incisional hernia did not differ significantly between fascial closure with slow and extra long-term absorbable suture (p = 0.111). Serious adverse events related to study intervention occurred in five patients (5.1%) from treatment groups II and III. Wound healing disorders were more frequently seen after onlay mesh implantation on the day of discharge (p = 0.010) and three (p = 0.009) and six (p = 0.023) months postoperatively. The existing evidence on prophylactic mesh augmentation in patients undergoing AAA-repair via midline laparotomy probably needs critical review. As the implementation of new RCTs is considered difficult due to the increasing number of endovascular AAA treated, registry studies could help to collect and evaluate data in cases of open AAA-repair. Comparisons between prophylactic mesh implantation and the small bite technique are also required. Trial registration: ClinicalTrials.gov Identifier: NCT01353443. Funding Sources: Aesculap AG, Tuttlingen, Germany.Entities:
Keywords: Abdominal; Aortic aneurysm; Fascial suture closure; Incisional hernia; Onlay mesh; Randomised controlled trial
Mesh:
Year: 2021 PMID: 34287760 PMCID: PMC9213335 DOI: 10.1007/s13304-021-01125-0
Source DB: PubMed Journal: Updates Surg ISSN: 2038-131X
Fig. 1CONSORT flow diagram of the trial
Baseline characteristics
| Total ( | Group I ( | Group II ( | Group III ( | ||
|---|---|---|---|---|---|
| Age (years) | 69.29 (8.15) | 67.37 (9.55) | 70.53 (7.80) | 70.20 (6.69) | 0.208c |
| BMI (kg/m2)* | 103 (99.04%) | 26.82 (2.94) | 26.58 (4.04) | 27.74 (4.82) | 0.447c |
| BMI > 30 kg/m2 | 22 (21.15%) | 6 (17.1) | 7 (20.6) | 9 (25.7) | 0.677a |
| Smoker | 49 (47.12%) | 13 (38.2%) | 20 (58.8%) | 16 (45.7%) | 0.227a |
| Alcohol consumption | 68 (65.38%) | 22 (62.9%) | 23 (69.7%) | 23 (69.7%) | 0.784a |
| Frequency of alcohol consumption | |||||
| Less than once weekly | 15 (14.42%) | 5 (22.7%) | 4 (17.4%) | 6 (26.1%) | 0.488b |
| Once weekly | 18 (17.31%) | 8 (36.4%) | 4 (17.4%) | 6 (26.1%) | |
| 2–6 weekly | 23 (22.12%) | 4 (18.2%) | 11 (47.8%) | 8 (34.8%) | |
| Daily | 12 (11.54%) | 5 (22.7%) | 4 (17.4%) | 3 (13.0) | |
| Insulin-dependent diabetes | 4 (3.85%) | 2 (5.9%) | 0 (0.0%) | 2 (5.9%) | 0.542b |
| COPD | 16 (15.38%) | 7 (20.0%) | 4 (12.5%) | 5 (15.2%) | 0.696a |
| ASA classification | 1.000b | ||||
| II | 41 (39.43%) | 14 (40.0%) | 14 (41.2%) | 13 (38.2%) | |
| III | 61 (58.65%) | 20 (57.1%) | 20 (58.8%) | 21 (61.8%) | |
| IV | 1 (0.96%) | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | |
| Unspecified | 1 (0.96%) | 0 (0.0%) | 0 (0.0%) | 1 (2.9%) | |
| Pulmonary diseases | 15 (14.42%) | 7 (20.6%) | 3 (9.1%) | 5 (14.7%) | 0.417a |
| Gastrointestinal diseases | 11 (10.58%) | 4 (11.4%) | 3 (9.4%) | 4 (11.8%) | 1.000b |
| Diseases of the urinary tract | 12 (11.54%) | 3 (8.6%) | 6 (18.2%) | 3 (8.8%) | 0.474b |
| Hemato-oncologic diseases | 3 (2.88%) | 1 (2.9%) | 1 (3.0%) | 1 (2.9%) | 1.000b |
| Endocrine diseases | 23 (22.12%) | 8 (22.9%) | 8 (24.2%) | 7 (20.6%) | 0.937a |
| Immune mediated diseases | 1 (0.96%) | 1 (2.9%) | 0 (0.0%) | 0 (0.0%) | 1.000b |
| Skin diseases | 6 (5.77%) | 2 (5.7%) | 3 (9.1%) | 1 (2.9%) | 0.522b |
| Disorders of muscle, skeleton and connective tissue | 9 (8.65%) | 2 (5.9%) | 2 (6.1%) | 5 (14.7%) | 0.499b |
| Further diseases influencing wound healing | 2 (1.92%) | 1 (3.1%) | 1 (3.2%) | 0 (0.0%) | 0.544b |
Data are number of patients (%) or mean (SD). Bold indicates test for even distribution between the groups by Chi2 test (a), Fisher’s exact test (b) or One-way ANOVA (c). Indicator for unequally distributed baseline characteristics was a p value from ≤ .2
ASA American Society of Anesthesiologists, BMI body mass index, COPD chronic obstructive pulmonary disease
*Number of patients who submitted a statement to this effect is 103
**Number of patients who submitted a statement to this effect is 43
***Including 32 abdominal operations via approaches other than median laparotomy
Fig. 2Kaplan–Meier curve for the probability of an event-free time. Comparison of the three treatment groups MonoPlus (group I), Monoplus and Olay Mesh Reinforcement (group II) and MonoMax (group III) based on the primary event “incision hernia within 24 months”
Incidence of incisional hernia in all patients included in intention-to-treat analysis
| Rate of primary event (%) | Hazard ratio (95% CI) | ||
|---|---|---|---|
| Adjusted cox-regression | |||
| Onlay mesh (group II) vs no onlay mesh (group I and III) | 2/32 (6.25) vs 14/67 (20.90) | 2.519 (0.455; 13.939) | 0.290 |
| MonoPlus (group I and group II) vs Monomax (group III) | 6/66 (9.09) vs 10/33 (30.30) | 2.666 (0.797; 8.912) | 0.111 |
| Male vs female | 15/94 (15.96) vs 1/10 (10.00) | 0.498 (0.063; 3.961) | 0.510 |
| Age | 1.171 (0.558; 2.457) | 0.677 | |
| Sensitivity analysis | |||
| MonoPlus (group I) vs Monoplus and onlay mesh (group II) | 4/34 (11.76) vs 2/32 (6.25) | 2.422 (0.442; 13.281) | 0.308 |
| MonoMax (group III) vs Monoplus and onlay mesh (group II) | 10/33 (30.30) vs 2/32 (6.25) | 6.364 (1.379; 29.376) | |
| Male vs female | 15/94 (15.96) vs 1/10 (10.00) | 0.342 (0.032; 3.607) | 0.372 |
| Age (unit = 10 years) | 0.841 (0.407; 2.405) | 0.737 | |
| Daily number of cigarettes (unit = 1 cigarette) | 0.965 (0.059; 1.587) | 0.249 | |
| Cardiovascular disease (no vs yes) | 5/37 (13.51) vs 11/65 (16.92) | 0.923 (0.250; 3.402) | 0.904 |
| Malignancy (no vs yes) | 15/93 (16.13) vs 0/7 (0.00) | Incalculable | 0.995 |
| Previous surgery (no vs yes) | 4/20 (20.00) vs 12/84 (14.29) | 1.992 (0.463; 8.576) | 0.355 |
Calculated using a Cox regression model with age and gender as covariates. Also sensitivity analyses with a Cox regression model adjusted for baseline characteristics (covariates) unequally distributed between the groups (indicator was a p-value from ≤ 0.2)
ITT intention to treat, CI confidence interval
Fig. 3Kaplan–Meier curve for the probability of an event-free time. Comparison of onlay mesh reinforcement (group II) versus no onlay mesh reinforcement (group I and III) a and of MonoPlus (group I and II) versus MonoMax (group III) b in regards to the secondary event “incision hernia within 12 months”
Serious adverse events
| Complication | Treatment | Study group |
|---|---|---|
| With relation to study intervention ( | ||
| Fascial dehiscence with bowel incarceration ( | Relaparotomy, bowel resection | II |
| Symptomatic incisional hernia ( | Relaparotomy, mesh implantation | III, III |
| Infected seroma* ( | Surgical revision, irrigation, mesh removal ( | II, II |
| Without relation to study intervention | ||
| Abdominal | ||
| Bleeding from aortic anastomosis ( | Relaparotomy, suture | |
| Partial occlusion of aorto-iliac graft ( | Relaparotomy, repeat aorto-bi-iliac reconstruction | |
| Bride ileus ( | Relaparotomy, adhesiolysis | |
| Rectosigmoid ischemia ( | Relaparotomy, bowel resection | |
| Bowel paralysis ( | Pharmaceutical | |
| Malpositioned urethral catheter with urethral injury ( | Cystoscopy, bladder irrigation via transurethral catheter | |
| Enteritis ( | Saline hydration, pharmaceutical | |
| Colitis ( | Antibiosis | |
| Pulmonary ( | ||
| Pneumonia ( | Antibiosis | |
| Peripheral pulmonary artery embolism due to deep vein thrombosis ( | Anticoagulation | |
| Renal ( | ||
| Worsening of pre-existing kidney dysfunction** ( | Saline hydration, pharmaceutical | |
| Cardiologic ( | ||
| Myocardial infarction ( | Pharmaceutical | |
| Cardiac arrest ( | CPR, intensive care management | |
| 3rd degree AV block ( | Pacemaker implantation | |
| Neurologic ( | ||
| Postoperative delirium ( | Pharmaceutical | |
| Others ( | ||
| Catheter infection ( | Antibiosis | |
| Skin eczema ( | Pharmaceutical | |
| Disease of femoro-popliteal arteries ( | ||
| Stage III POD ( | Surgical revascularization | |
| Embolizing popliteal aneurysm ( | Femoro-popliteal bypass, secondary thigh amputation | |
| Femoro-popliteal graft infection ( | Antibiosis |
*Required mesh removal in one case
**Without necessity of dialysis
CPR cardiopulmonary resuscitation, POD peripheral occlusive disease